Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical A
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ... ... ReliantHeart, Inc. , an innovative supplier of advanced mechanical circulatory assist ... LVAD (HA5) to the 68th consecutive implant, there has been no evidence of de ... is referred to as de novo thrombus. De novo thrombus can hide under the ...
(Date:6/25/2015)... DUBLIN , June 25, 2015 ... Markets ( http://www.researchandmarkets.com/research/vxtfvv/2015_market ) has announced the ... Analysis of the Global Cancer Diagnostics ... CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
(Date:6/25/2015)... ... 25, 2015 , ... The American Brain Tumor Association announced ... Family Conference, Providing and Pursuing Answers: Advances in Research, Treatment and Care. The ... July 24-25, 2015. , “As advances in research accelerate the arrival of precision ...
(Date:6/25/2015)...  BioMed Realty Trust, Inc. (NYSE: BMR ) ... a world leader in genomics focused on improving human ... signed a 20-year lease for a 155,000 square foot ... Cambridge, England . The project will provide Illumina ... workforce in the dynamic research cluster anchored by Cambridge ...
Breaking Biology Technology:HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3Nationally Recognized Brain Tumor Experts to Speak at American Brain Tumor Association Patient and Family Conference 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3
... Small Companies In America, UNION CITY, Calif., Oct. ... products company manufacturing point-of-care,blood chemistry analysis systems, announced today ... named "Entrepreneur of,the Year" by Forbes Magazine in its ... ranked eleventh of the "200 Best Small Companies in,America." ...
... Held by GlaxoSmithKline Since June 2006, PHILADELPHIA ... The Thomson Corporation (NYSE: TOC ; TSX: ... worldwide research and,business communities, today announced the availability ... on drugs and therapies. "Who is,Making the Biggest ...
... AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX: ... F. McElroy,has resigned as Chairman and a director of ... had a long involvement with the Company since its,amalgamation ... "On behalf of the Company, I thank him for ...
Cached Biology Technology:Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3Helix BioPharma Chairman resigns 2
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... 2011 (Rome, Italy) -- Researchers speaking in the second ... Pathogenesis, Treatment and Prevention (IAS 2011) have today provided ... and alerted delegates to the challenges that developing countries ... antiretroviral therapy (ART) coverage. The presentations reflect the ...
... Small-scale fisheries could pose a more serious threat to ... University of Exeter, published today (19 July) in the ... shows that tens of thousands of turtles from across ... small-scale fisheries. Focusing on fisheries in Peru, the ...
... use various appendages to move across surfaces prior to ... jerky form of movement known as "twitching" motility, which ... called type IV pili, or TFP. ... a professor of bioengineering and of chemistry and biochemistry ...
Cached Biology News:Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 2Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 3Study shows small-scale fisheries' impact on marine life 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
MAb to Myoglobin Cardiac...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: